EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): StudyFirst CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium (90Y) Anditixafortide (PentixaTher) 22.11.2023 / 16:02 CET/CESTThe issuer is solely responsible for the content of this announcement.Berlin/Würzburg, 22 November 202.
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word: Study
First CNS Lymphoma Patient Dosed in Phase I/II PTT101 Study with Yttrium Anditixafortide .
The company founder and Chairman of the Supervisory Board of the radiation and medical technology specialist Eckert & Ziegler is moving from the parent company to the spin-off subsidiary for clinical.
EQS-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word: AGM/EGM/Personnel
ckert & Ziegler: Annual General Meeting Approves Dividend of EUR 0.50 per Share.. | June 7, 2023